Fluorodeoxyglucose positron emission tomography helped determine the outcomes of chemotherapy treatment for patients with bone sarcomas.  “The utility of a tumor pre-therapy [fluorodeoxyglucose positron emission tomography] FDG PET scan as a biomarker for the outcome of patients with sarcoma was strengthened by a mid-therapy scan to evaluate the interim treatment response,” the investigators wrote. {read more here}